TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0

Reuters

2025/06/09

TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0

TAMPA, Fla., June 9, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA), an innovative Phase 3 immune-oncology company, announced that the FDA has lifted the manufacturing-related partial clinical hold on its Phase 3 trial for IFx-2.0, aimed at treating advanced or metastatic Merkel cell carcinoma. This pivotal trial will now proceed under a Special Protocol Assessment Agreement with the FDA, evaluating IFx-2.0 alongside Keytruda® as a first-line treatment. The removal of the hold also unlocks the second tranche of funds from a $12.5 million PIPE financing, specifically providing TuHURA with an additional $2.23 million. This financial boost facilitates the initiation and activation of clinical sites across the United States, advancing TuHURA's mission to overcome resistance in cancer immunotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05232) on June 09, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542810103"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542810103\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542810103?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542810103","market":"us","top_or_hot":-1,"title":"TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TAMPA, Fla., June 9, 2025 - <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences, Inc.</a> (NASDAQ:HURA), an innovative Phase 3 immune-oncology company, announced that the FDA has lifted the manufacturing-related partial clinical hold on its Phase 3 trial for IFx-2.0, aimed at treating advanced or metastatic Merkel cell carcinoma. This pivotal trial will now proceed under a Special Protocol Assessment Agreement with the FDA, evaluating IFx-2.0 alongside Keytruda® as a first-line treatment. The removal of the hold also unlocks the second tranche of funds from a $12.5 million PIPE financing, specifically providing TuHURA with an additional $2.23 million. This financial boost facilitates the initiation and activation of clinical sites across the United States, advancing TuHURA's mission to overcome resistance in cancer immunotherapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05232) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-09 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TAMPA, Fla., June 9, 2025 - <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences, Inc.</a> (NASDAQ:HURA), an innovative Phase 3 immune-oncology company, announced that the FDA has lifted the manufacturing-related partial clinical hold on its Phase 3 trial for IFx-2.0, aimed at treating advanced or metastatic Merkel cell carcinoma. This pivotal trial will now proceed under a Special Protocol Assessment Agreement with the FDA, evaluating IFx-2.0 alongside Keytruda® as a first-line treatment. The removal of the hold also unlocks the second tranche of funds from a $12.5 million PIPE financing, specifically providing TuHURA with an additional $2.23 million. This financial boost facilitates the initiation and activation of clinical sites across the United States, advancing TuHURA's mission to overcome resistance in cancer immunotherapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05232) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL9Vnkv2:1","article_id":"2542810103","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542810103","pubTimestamp":1749470454,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on June 09, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HURA":"TuHURA Biosciences, Inc."},"translate_title":"FDA解除IFX-2.0 3期试验的部分临床搁置后，TuHURA Biosciences获得了223万美元的额外资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HURA":0.9},"content_text":"TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0\n    \n\n        TAMPA, Fla., June 9, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA), an innovative Phase 3 immune-oncology company, announced that the FDA has lifted the manufacturing-related partial clinical hold on its Phase 3 trial for IFx-2.0, aimed at treating advanced or metastatic Merkel cell carcinoma. This pivotal trial will now proceed under a Special Protocol Assessment Agreement with the FDA, evaluating IFx-2.0 alongside Keytruda® as a first-line treatment. The removal of the hold also unlocks the second tranche of funds from a $12.5 million PIPE financing, specifically providing TuHURA with an additional $2.23 million. This financial boost facilitates the initiation and activation of clinical sites across the United States, advancing TuHURA's mission to overcome resistance in cancer immunotherapy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05232) on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}